Our bodies are constantly and successfully fighting off the development of cells that lead to tumours — but when there is disruption to this process cancer is free to develop.

Walter and Eliza Hall Institute researchers, led by Dr Sandra Nicholson and Dr Nicholas Huntington, together with colleagues from the Queensland Institute of Medical Research, are investigating ways to ‘switch on’ our Natural Killer (NK) cells.

Natural Killer cells exist to detect and then destroy any deviant cells in our bodies before those cells go on to develop into tumours or before infection spreads, Dr Nicholson said.

“Natural Killer cells are a key part of our immune system that locate other cells posing a danger to health either because they are infected or because they are becoming a cancer cell,” she said.

However, it is known that abnormal cells sometimes escape the immune system and develop into a cancer.

The researchers identified a protein ‘brake’ within Natural Killer cells that controls their ability to destroy their target tumour cells.

Find your dream job in the space industry. Check our Space Job Board »

In their paper published in Nature Immunology, they showed that when the brake was removed in an experimental model, the NK cells were better able to protect the body against metastatic melanoma.

Natural Killer cells rely on a growth factor called Interleukin 15 (IL15) to activate. Dr Nicholson and Dr Huntington’s research has shown that an inhibitor protein made inside the Natural Killer cells limits the ability of the NK cell to respond to IL15 and therefore kill cancer cells. By identifying for the first time how this protein inhibits NK cell responses, they now hope that a drug can be developed that will improve the NK cells’ response to this growth factor and help patients fight cancer with their own immune system.

“This is about learning how to activate the NK cells of the individual patient and boost their immune system to tackle the disease,” Dr Huntington said.

“We are hopeful our research will lead to new immunotherapies that supercharge the body’s Natural Killer cell, and maintain it in a highly active state to more efficiently and specifically fight cancer.”


Source: Walter and Eliza Hall Institute

Journal Reference:

  1. Rebecca B Delconte, Tatiana B Kolesnik, Laura F Dagley, Jai Rautela, Wei Shi, Eva M Putz, Kimberley Stannard, Jian-Guo Zhang, Charis Teh, Matt Firth, Takashi Ushiki, Christopher E Andoniou, Mariapia A Degli-Esposti, Phillip P Sharp, Caroline E Sanvitale, Giuseppe Infusini, Nicholas P D Liau, Edmond M Linossi, Christopher J Burns, Sebastian Carotta, Daniel H D Gray, Cyril Seillet, Dana S Hutchinson, Gabrielle T Belz, Andrew I Webb, Warren S Alexander, Shawn S Li, Alex N Bullock, Jeffery J Babon, Mark J Smyth, Sandra E Nicholson, Nicholas D Huntington. CIS is a potent checkpoint in NK cell–mediated tumor immunity. Nature Immunology, 2016; DOI: 10.1038/ni.3470